Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin - PubMed (original) (raw)
Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin
Naiane do Nascimento Goncalves et al. Anticancer Agents Med Chem. 2014.
Abstract
Background: Oral cancer is the most common type of head and neck cancer and its high rate of mortality and morbidity is closely related to the processes of angiogenesis and tumor metastasis. The overexpression of the pro-angiogenic genes, HIF-1α and VEGF, and pro-metastatic gene, ROCK-1, are associated with unfavorable prognosis in oral carcinoma. Melatonin has oncostatic, antiangiogenic and antimetastatic properties in several types of neoplasms, although its relationship with oral cancer has been little explored. This study aims to analyze the expression of the genes HIF-1α, VEGF and ROCK-1 in cell lines of squamous cell carcinoma of the tongue, after treatment with melatonin.
Methods: SCC9 and SCC25 cells were cultured and cell viability was assessed by MTT assay, after treatment with 100 μM of CoCl2 to induce hypoxia and with melatonin at different concentrations. The analysis of quantitative RT-PCR and the immunocytochemical analysis were performed to verify the action of melatonin under conditions of normoxia and hypoxia, on gene and protein expression of HIF-1α, VEGF and ROCK-1.
Results: The MTT assay showed a decrease in cell viability in both cell lines, after the treatment with melatonin. The analysis of quantitative RT-PCR indicated an inhibition of the expression of the pro-angiogenic genes HIF-1α (P < 0.001) and VEGF (P < 0.001) under hypoxic conditions, and of the pro-metastatic gene ROCK-1 (P < 0.0001) in the cell line SCC9, after treatment with 1 mM of melatonin. In the immunocytochemical analysis, there was a positive correlation with gene expression data, validating the quantitative RT-PCR results for cell line SCC9. Treatment with melatonin did not demonstrate inhibition of the expression of genes HIF-1α, VEGF and ROCK-1 in line SCC25, which has different molecular characteristics and greater degree of malignancy when compared to the line SCC9.
Conclusion: Melatonin affects cell viability in the SCC9 and SCC25 lines and inhibits the expression of the genes HIF-1α, VEGF and ROCK-1 in SCC9 line. Additional studies may confirm the potential therapeutic effect of melatonin in some subtypes of oral carcinoma.
Similar articles
- Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines.
Jardim-Perassi BV, Lourenço MR, Doho GM, Grígolo IH, Gelaleti GB, Ferreira LC, Borin TF, Moschetta MG, Pires de Campos Zuccari DA. Jardim-Perassi BV, et al. Anticancer Agents Med Chem. 2016;16(3):347-58. doi: 10.2174/1871520615666150511094201. Anticancer Agents Med Chem. 2016. PMID: 25963143 - Jianpi Jiedu decoction, a traditional Chinese medicine formula, inhibits tumorigenesis, metastasis, and angiogenesis through the mTOR/HIF-1α/VEGF pathway.
Peng W, Zhang S, Zhang Z, Xu P, Mao D, Huang S, Chen B, Zhang C, Zhang S. Peng W, et al. J Ethnopharmacol. 2018 Oct 5;224:140-148. doi: 10.1016/j.jep.2018.05.039. Epub 2018 May 28. J Ethnopharmacol. 2018. PMID: 29852266 - Hypoxia-induced vascular endothelial growth factor secretion by retinal pigment epithelial cells is inhibited by melatonin via decreased accumulation of hypoxia-inducible factors-1α protein.
Lai YH, Hu DN, Rosen R, Sassoon J, Chuang LY, Wu KY, Wu WC. Lai YH, et al. Clin Exp Ophthalmol. 2017 Mar;45(2):182-191. doi: 10.1111/ceo.12802. Epub 2016 Aug 10. Clin Exp Ophthalmol. 2017. PMID: 27409056 - Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence.
Goradel NH, Asghari MH, Moloudizargari M, Negahdari B, Haghi-Aminjan H, Abdollahi M. Goradel NH, et al. Toxicol Appl Pharmacol. 2017 Nov 15;335:56-63. doi: 10.1016/j.taap.2017.09.022. Epub 2017 Sep 30. Toxicol Appl Pharmacol. 2017. PMID: 28974455 Review. - Relationship of Angiogenesis and Oral Squamous Cell Carcinoma.
Marla V, Hegde V, Shrestha A. Marla V, et al. Kathmandu Univ Med J (KUMJ). 2015 Apr-Jun;13(50):178-85. doi: 10.3126/kumj.v13i2.16796. Kathmandu Univ Med J (KUMJ). 2015. PMID: 26643840 Review.
Cited by
- Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities.
Talib WH, Alsayed AR, Abuawad A, Daoud S, Mahmod AI. Talib WH, et al. Molecules. 2021 Apr 25;26(9):2506. doi: 10.3390/molecules26092506. Molecules. 2021. PMID: 33923028 Free PMC article. Review. - Inhibition of VEGF-Induced VEGFR-2 Activation and HUVEC Migration by Melatonin and Other Bioactive Indolic Compounds.
Cerezo AB, Hornedo-Ortega R, Álvarez-Fernández MA, Troncoso AM, García-Parrilla MC. Cerezo AB, et al. Nutrients. 2017 Mar 8;9(3):249. doi: 10.3390/nu9030249. Nutrients. 2017. PMID: 28282869 Free PMC article. - Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.
Pathak A, Pal AK, Roy S, Nandave M, Jain K. Pathak A, et al. Stem Cells Int. 2024 Jan 4;2024:9077926. doi: 10.1155/2024/9077926. eCollection 2024. Stem Cells Int. 2024. PMID: 38213742 Free PMC article. Review. - Melatonin is a potential oncostatic agent to inhibit HepG2 cell proliferation through multiple pathways.
Ammar OA, El-Missiry MA, Othman AI, Amer ME. Ammar OA, et al. Heliyon. 2022 Jan 31;8(1):e08837. doi: 10.1016/j.heliyon.2022.e08837. eCollection 2022 Jan. Heliyon. 2022. PMID: 35141433 Free PMC article. - Potential of Melatonin as Adjuvant Therapy of Oral Cancer in the Era of Epigenomics.
Capote-Moreno A, Ramos E, Egea J, López-Muñoz F, Gil-Martín E, Romero A. Capote-Moreno A, et al. Cancers (Basel). 2019 Nov 2;11(11):1712. doi: 10.3390/cancers11111712. Cancers (Basel). 2019. PMID: 31684096 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical